Anne S R van Lindert
Overview
Explore the profile of Anne S R van Lindert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haaksman M, Ham L, Brom L, Baars A, van Basten J, van den Borne B, et al.
Support Care Cancer
. 2024 Mar;
32(4):214.
PMID: 38446248
Objective: To assess the degree of openness of communication about illness and death between patients with advanced cancer and their relatives during the last three months of the patient's life,...
2.
Verheijden R, Cabane Ballester A, Smit K, van Eijs M, Bruijnen C, van Lindert A, et al.
J Natl Cancer Inst
. 2023 Nov;
116(4):573-579.
PMID: 38001030
Background: Although animal experiments suggest beneficial effects of physical activity (PA) on antitumor immunity, little is known about the effects of PA on immune checkpoint inhibitor (ICI) toxicity and effectiveness...
3.
van Eijs M, Verheijden R, van der Wees S, Nierkens S, van Lindert A, Suijkerbuijk K, et al.
Cancer Immunol Immunother
. 2023 Oct;
72(12):4049-4064.
PMID: 37794264
Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of advanced malignancies, but come with a diverse spectrum of immune-related adverse events (irAEs). Mechanistic studies can aid the transition from...
4.
Tomassen M, Damen P, Verkooijen H, Peters M, van der Stap J, van Lindert A, et al.
Acta Oncol
. 2023 Mar;
62(3):237-244.
PMID: 36927251
'Trials-within-Cohorts' (TwiCs), previously known as 'cohort multiple randomized controlled trials' is a pragmatic trial design, supporting an efficient and representative recruitment of patients for (future) trials. To our knowledge, the...
5.
de Jong C, Herder G, van Haarlem S, van der Meer F, van Lindert A, Ten Heuvel A, et al.
Genes (Basel)
. 2023 Jan;
14(1).
PMID: 36672910
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, disabling side effect in non-small cell lung cancer (NSCLC) patients treated with platinum-based therapy. There is increasing evidence for associations between genetic...
6.
Koomen B, de Boer M, van Dooijeweert C, van Lindert A, Deckers I, Voorham Q, et al.
Virchows Arch
. 2022 Nov;
482(4):707-720.
PMID: 36370167
Programmed death ligand-1 (PD-L1) immunostaining, which aids clinicians in decision-making on immunotherapy for non-small cell lung cancer (NSCLC) patients, is sometimes performed on cytological specimens. In this study, differences in...
7.
Damen P, Suijkerbuijk K, van Lindert A, Eppinga W, El Sharouni S, Verhoeff J
Anticancer Res
. 2022 Oct;
42(10):4795-4804.
PMID: 36191990
Background/aim: Recent studies described the safety and clinical utility of combined anti-programmed cell death protein-1 (anti-PD1) checkpoint inhibition with radiotherapy. However, long-term follow-up data are lacking. Abscopal effects have been...
8.
van Eijs M, van der Wagen L, Mous R, Leguit R, van de Corput L, van Lindert A, et al.
Cancer Immunol Immunother
. 2022 Jun;
72(1):249-255.
PMID: 35691988
Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present...
9.
Van Amsterdam W, Verhoeff J, Harlianto N, Bartholomeus G, Puli A, de Jong P, et al.
Sci Rep
. 2022 Apr;
12(1):5848.
PMID: 35393451
Randomized Controlled Trials (RCT) are the gold standard for estimating treatment effects but some important situations in cancer care require treatment effect estimates from observational data. We developed "Proxy based...
10.
de Jong C, Chargi N, Herder G, van Haarlem S, van der Meer F, van Lindert A, et al.
J Cachexia Sarcopenia Muscle
. 2022 Mar;
13(3):1554-1564.
PMID: 35301821
Background: Chemotherapy-induced toxicities frequently occur in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Low skeletal muscle mass (SMM) has been associated with a higher incidence of toxicities...